HealthcarePartially correct
“REC-3964 Clostridioides difficile Infection — Phase 2 study initiation in the fourth quarter of 2024 and preliminary data readout by the end of 2025.”
Nasdaq-listed AI-driven 'TechBio' drug discovery company; guidance issued under co-founder and CEO Chris Gibson
Said Jun 24, 2024Deadline Dec 31, 2025Recursion press release, 'Recursion Gives Guidance on Seven Clinical Readouts within ~18 Months', Download Day, 24 June 2024
The Phase 2 ALDER trial did start on schedule — first patient dosed in October 2024 — but Recursion discontinued the program in its Q1 2025 update (May 2025), citing low recurrence rates with existing therapies and seeking out-licensing, so no preliminary efficacy readout was delivered by the end of 2025.